Sign inJoin
Company / Finance

Adicet Bio, Inc.

ACET · NASDAQ

Adicet is trying to turn prula-cel from a promising autoimmune CAR-T idea into a pivotal-trial story before its disclosed runway reaches the second half of 2027.

FollowAdd to WatchlistAsk Question
NASDAQACETCoverage BootstrapBiotechnologyCell TherapyCAR-T
Latest ReportMay 13, 2026Adicet Bio: the lupus CAR-T readout racing a 2027 cash runwayView report ->Total Reports1Published reportView all ->Active Discussions0No visible comments yetView discussions ->Member WorkspaceLockedFinancials, timeline, comparisons, scorecard, and discussion require a paid login.View access ->
Company filters1 of 1 reports match
Clear filters
Selected tags
NasdaqCar T
Clear tags
MatchAny tagAll tags
Latest Thesis

Adicet Bio: the lupus CAR-T readout racing a 2027 cash runway

Adicet is trying to turn prula-cel from a promising autoimmune CAR-T idea into a pivotal-trial story before its disclosed runway reaches the second half of 2027.

May 13, 2026Research reportSlides available
Read reportOpen slidesDiscussion (0)
Adicet Bio, Inc.Bio: the lupus CAR-T readout racing a 2027 cash runwayMay 13, 2026
Member workspace

Financials and workspace tools are for paid members.

Paid login unlocks company financials, filing timeline, peer comparison, scorecard, and discussion. Valuation remains admin-only while we finalize market-data licensing.

Sign in to continue

Recent Reports

Compact report index for this company.

View all 1 reports ->
ReportTypeUpdatedReadActions
Adicet Bio: the lupus CAR-T readout racing a 2027 cash runwayAdicet is trying to turn prula-cel from a promising autoimmune CAR-T idea into a pivotal-trial story before its disclosed runway reaches the second half of 2027.NASDAQMay 13, 2026Research reportReadSlides